<DOC>
	<DOCNO>NCT00097968</DOCNO>
	<brief_summary>Everolimus immunosuppressive drug study prevent acute rejection happen heart transplantation . It usually use combination immunosuppressive drug cyclosporine . The purpose study evaluate change kidney function begin everolimus , determine effective Neoral® ( cyclosporine ) dose take everolimus , adult cardiac transplant patient transplanted heart least 1 year cardiac allograft vasculopathy .</brief_summary>
	<brief_title>Safety/Efficacy Everolimus Neoral® Adult Cardiac Transplant Patients With Established Allograft Vasculopathy</brief_title>
	<detailed_description />
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Male female adult establish cardiac allograft vasculopathy define new luminal irregularity coronary angiography . Patient must statins study entry . Patient 12 month posttransplant . Patient serum creatinine value &gt; 2.0 mg/dL . Patient biopsyproven acute rejection episode ( &gt; = ISHLT 3A ) within 6 month prior study entry . Patient receive investigational drug within 4 week prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>transplant , heart , adult , everolimus</keyword>
	<keyword>allograft rejection</keyword>
</DOC>